Skip to main content

Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents

Evaluate the efficacy and safety of subcutaneous ketamine added to usual treatment in the management of depressive episodes with suicidal ideation or behavior in adolescent patients, compared to usual treatment added to placebo (midazolam).

Status
planned
Phase
Phase 3
Institution
Federal University of São Paulo
Start date
2025-05-01
End date
2028-04-01
Registry ID
NCT06957704

View trial record

Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.